Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Azitra Inc (AZTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AZTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.89M USD | Price to earnings Ratio 0.01 | 1Y Target Price 3.5 |
Price to earnings Ratio 0.01 | 1Y Target Price 3.5 | ||
Volume (30-day avg) 479993 | Beta - | 52 Weeks Range 0.23 - 8.79 | Updated Date 03/15/2025 |
52 Weeks Range 0.23 - 8.79 | Updated Date 03/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 92.33 |
Earnings Date
Report Date 2025-03-14 | When - | Estimate - | Actual -0.3138 |
Profitability
Profit Margin - | Operating Margin (TTM) -35470.4% |
Management Effectiveness
Return on Assets (TTM) -93.46% | Return on Equity (TTM) -222.3% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value 344802 | Price to Sales(TTM) 579.2 |
Enterprise Value 344802 | Price to Sales(TTM) 579.2 | ||
Enterprise Value to Revenue 45.97 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 7626060 | Shares Floating 6838913 |
Shares Outstanding 7626060 | Shares Floating 6838913 | ||
Percent Insiders 10.7 | Percent Institutions 8.92 |
Analyst Ratings
Rating 4 | Target Price 3.5 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Azitra Inc
Company Overview
History and Background
Azitra, Inc. is a clinical-stage medical dermatology company that was founded in 2014. It focuses on developing therapies to treat skin diseases by harnessing the skin microbiome. The company has transitioned from early-stage research to clinical trials.
Core Business Areas
- Therapeutic Development: Azitra focuses on developing novel therapies based on the skin microbiome to treat skin conditions.
Leadership and Structure
The company is led by a management team with experience in dermatology and microbiome research. Information on the full organizational structure is not available publicly.
Top Products and Market Share
Key Offerings
- ATR-12: A genetically modified strain of Staphylococcus epidermidis being developed for the treatment of Netherton syndrome. Clinical trials are ongoing. Market share data is not yet available as the product is not yet commercialized. Competitors targeting Netherton syndrome are limited, but include companies developing biologics and other targeted therapies for rare skin diseases.
- ATR-04: In preclinical development for the treatment of skin cancer. Market share data is not available as the product is in the preclinical stage. Competitors include companies focusing on immunotherapies, targeted therapies, and other novel approaches to skin cancer treatment.
Market Dynamics
Industry Overview
The medical dermatology industry is characterized by increasing innovation, including microbiome-based therapies, biologics, and targeted small molecules. The market is competitive, with a mix of large pharmaceutical companies and smaller biotechnology firms.
Positioning
Azitra is positioned as a pioneer in microbiome-based therapies for dermatological conditions. Its competitive advantage lies in its proprietary platform for engineering skin bacteria.
Total Addressable Market (TAM)
The global dermatology market is estimated at over $30 billion, with specific segments like Netherton Syndrome and skin cancer representing significant opportunities. Azitra is positioned to capture a portion of this market through its novel therapies.
Upturn SWOT Analysis
Strengths
- Proprietary microbiome engineering platform
- Focus on underserved dermatological conditions
- Experienced management team
- Clinical-stage pipeline
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Potential regulatory hurdles
- Limited commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other dermatological conditions
- Positive clinical trial results
- Increased awareness of microbiome-based therapies
Threats
- Competition from established dermatology companies
- Clinical trial failures
- Changes in regulatory landscape
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- LEO Pharma (Not Publicly Traded)
- Galderma (Not Publicly Traded)
- Sanofi (SNY)
Competitive Landscape
Azitra faces competition from larger, established dermatology companies with greater resources and marketing capabilities. Azitra differentiates itself through its focus on microbiome-based therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is marked by preclinical development and the progress of ATR-12 through clinical trials.
Future Projections: Future growth is dependent on clinical trial outcomes and potential partnerships. Analyst estimates are speculative given the early stage of the company.
Recent Initiatives: Focus on progressing ATR-12 through clinical trials and expanding its preclinical pipeline.
Summary
Azitra is a clinical-stage biotechnology company with a focus on microbiome-based therapies for dermatological conditions. Its strength lies in its proprietary technology and focus on underserved markets. However, it faces risks associated with clinical trial success and competition from larger companies. Positive clinical data and strategic partnerships are crucial for future growth.
Similar Companies
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company Website
- ClinicalTrials.gov
- Publicly Available SEC Filings (if any)
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is estimated and may not be precise. The AI-based rating is a subjective assessment and should be considered in conjunction with independent research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Azitra Inc
Exchange NYSE MKT | Headquaters Branford, CT, United States | ||
IPO Launch date 2023-06-16 | President, CEO & Director Mr. Francisco D. Salva | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://azitrainc.com |
Full time employees 12 | Website https://azitrainc.com | ||
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.